Biotech News

Annovis Announces Pricing of $21.0 Million Public Offering

Annovis Bio (ANVS)Annovis BioFinancing

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of (i) 19,000,000 shares of its common stock and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,000,000 shares of its common stock, and (ii) accompanying warrants to purchase up to 21,000,000 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.00, and the combined offering price of each Pre-Funded Warrant to purchase one share of common stock and accompanying warrant is $0.9999, which equals the combined offering price per share of common stock and accompanying warrant, less the $0.0001 per share exercise price of each Pre-Funded Warrant. Each accompanying warrant will be exercisable for one share of common stock at an exercise price of $1.00 per share of common stock, will be exercisable immediately upon issuance and will expire five years after the date of issuance. The Pre-Funded Warrants will be exercisable immediately upon issuance and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

Related news

Annovis Bio

Phase 3 Neurodegenerative Disease Company Annovis Bio is developing buntanetap, an oral candidate for Alzheimer’s disease and Parkinson’s disease. Through an RNA-targeting mechanism, buntanetap is designed to reduce translation of multiple neurotoxic proteins, including APP/amyloid beta, tau, alpha-synuclein, and TDP-43. Registrational...

Recent company news

Stock data

Close
0.75 USD
Market cap
79.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States